• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The regulatory state of nonalcoholic steatohepatitis and metabolism.非酒精性脂肪性肝炎的调控状态与代谢
Endocrinol Diabetes Metab. 2020 Oct 21;3(4):e00113. doi: 10.1002/edm2.113. eCollection 2020 Oct.
2
The efficacy of L-carnitine in patients with nonalcoholic steatohepatitis and concomitant obesity.左旋肉碱治疗非酒精性脂肪性肝炎伴肥胖患者的疗效。
Lipids Health Dis. 2023 Jul 12;22(1):101. doi: 10.1186/s12944-023-01867-3.
3
[Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes].[非酒精性脂肪性肝炎和脂肪变性在糖尿病前期和2型糖尿病患者中综合治疗的发病机制依据]
Wiad Lek. 2017;70(2):169-173.
4
INFLUENCE OF OXIDATIVE STRESS AND OBESITY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS.氧化应激和肥胖对非酒精性脂肪性肝炎患者的影响
Arq Gastroenterol. 2015 Jul-Sep;52(3):228-33. doi: 10.1590/S0004-28032015000300014.
5
Nonalcoholic Steatohepatitis Is the Most Rapidly Growing Indication for Liver Transplantation in Iranian Patients.非酒精性脂肪性肝炎是伊朗患者进行肝移植的增长最快的指征。
Exp Clin Transplant. 2022 May;20(5):487-494. doi: 10.6002/ect.2019.0205. Epub 2019 Oct 1.
6
The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.胆汁酸在非酒精性脂肪性肝病和非酒精性脂肪性肝炎中的作用。
Mol Aspects Med. 2017 Aug;56:34-44. doi: 10.1016/j.mam.2017.04.004. Epub 2017 May 5.
7
Nonalcoholic fatty liver disease: scintigraphy in the diagnosis of steatohepatitis.非酒精性脂肪性肝病：肝脂肪性肝炎的闪烁显像诊断。
Rev Assoc Med Bras (1992). 2021 Nov;67(11):1665-1669. doi: 10.1590/1806-9282.20210718.
8
Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives.非酒精性脂肪性肝病血清代谢组学特征研究：研究与临床展望
Metabolites. 2018 Feb 24;8(1):17. doi: 10.3390/metabo8010017.
9
Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma.可切除性肝内胆管细胞癌患者中非酒精性脂肪性肝炎的患病率。
J Gastrointest Surg. 2013 Apr;17(4):748-55. doi: 10.1007/s11605-013-2149-x. Epub 2013 Jan 25.
10
[The importance of AST / ALT rate in nonalcoholic steatohepatitis diagnosis].[谷草转氨酶/谷丙转氨酶比值在非酒精性脂肪性肝炎诊断中的重要性]
Arq Gastroenterol. 2002 Jan-Mar;39(1):22-6. doi: 10.1590/s0004-28032002000100005.

引用本文的文献

1
Machine learning based identification potential feature genes for prediction of drug efficacy in nonalcoholic steatohepatitis animal model.基于机器学习的非酒精性脂肪性肝炎动物模型药物疗效预测潜在特征基因鉴定。
Lipids Health Dis. 2024 Aug 24;23(1):266. doi: 10.1186/s12944-024-02231-9.
2
Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease.非酒精性脂肪性肝炎（NASH）- 复杂疾病驱动下拥挤临床领域的综述
Drug Des Devel Ther. 2021 Sep 22;15:3997-4009. doi: 10.2147/DDDT.S315724. eCollection 2021.
3
Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants.非酒精性脂肪性肝病中的氧化应激：营养素和食物污染物的作用。
Biomolecules. 2020 Dec 21;10(12):1702. doi: 10.3390/biom10121702.

本文引用的文献

1
Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.减肥干预措施与非酒精性脂肪性肝病生物标志物变化的关联：一项系统评价和荟萃分析。
JAMA Intern Med. 2019 Sep 1;179(9):1262-1271. doi: 10.1001/jamainternmed.2019.2248.
2
Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.共识：指南：在临床试验中检测、评估和管理非酒精性脂肪性肝炎患者疑似急性药物性肝损伤的最佳实践。
Aliment Pharmacol Ther. 2019 Mar;49(6):702-713. doi: 10.1111/apt.15153. Epub 2019 Feb 13.
3
Patients With Chronic Liver Disease Suggestive of Nonalcoholic Fatty Liver Disease May Be at Higher Risk for Drug-Induced Liver Injury.有非酒精性脂肪性肝病特征的慢性肝病患者可能具有更高的药物性肝损伤风险。
Clin Gastroenterol Hepatol. 2019 Dec;17(13):2814-2815. doi: 10.1016/j.cgh.2018.12.013. Epub 2018 Dec 20.
4
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.肥胖与非酒精性脂肪性肝病：从病理生理学到治疗学。
Metabolism. 2019 Mar;92:82-97. doi: 10.1016/j.metabol.2018.11.014. Epub 2018 Nov 29.
5
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.隐匿性肝硬化的难题：无治疗选择的不良结局。
J Hepatol. 2018 Dec;69(6):1365-1370. doi: 10.1016/j.jhep.2018.08.013. Epub 2018 Aug 23.
6
Noninvasive biomarkers in NAFLD and NASH - current progress and future promise.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的无创性生物标志物：当前进展与未来前景。
Nat Rev Gastroenterol Hepatol. 2018 Aug;15(8):461-478. doi: 10.1038/s41575-018-0014-9.
7
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的全球负担：趋势、预测、危险因素和预防。
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20.
8
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.非酒精性脂肪性肝病的诊断与管理：美国肝病研究协会的实践指南
Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29.
9
NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).NASPGHAN儿童非酒精性脂肪性肝病诊断与治疗临床实践指南：非酒精性脂肪性肝病专家委员会（ECON）及北美儿科胃肠病学、肝病学和营养学会（NASPGHAN）的建议
J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):319-334. doi: 10.1097/MPG.0000000000001482.
10
Trends in Obesity Prevalence Among Children and Adolescents in the United States, 1988-1994 Through 2013-2014.1988 - 1994年至2013 - 2014年美国儿童和青少年肥胖患病率趋势
JAMA. 2016 Jun 7;315(21):2292-9. doi: 10.1001/jama.2016.6361.

The regulatory state of nonalcoholic steatohepatitis and metabolism.

作者信息

Omokaro Stephanie O, Golden Julie K

机构信息

Division of Gastroenterology and Inborn Errors Products (DGIEP) OND CDER U.S. Food and Drug Administration Silver Spring MD USA.

Division of Metabolism and Endocrinology Products (DMEP) OND CDER U.S. Food and Drug Administration Silver Spring MD USA.

出版信息

Endocrinol Diabetes Metab. 2020 Oct 21;3(4):e00113. doi: 10.1002/edm2.113. eCollection 2020 Oct.

DOI:10.1002/edm2.113
PMID:33102795
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7576228/
Abstract
摘要